Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

MLA

Cortes, Jorge E., et al. “Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib.” Blood, vol. 140, no. 1, Number 1 Supplement 1, Nov. 2022, pp. 1495–97. EBSCOhost, https://doi.org/10.1182/blood-2022-157822.

APA

Cortes, J. E., Deininger, M. W., Lomaia, E., Moiraghi, B., Sutton, M. U., Pavlovsky, C., Chuah, C., Sacha, T., Lipton, J. H., McCloskey, J., Hochhaus, A., Rousselot, P., Rosti, G., de Lavallade, H., Rojas, C., Turkina, A., Maness, L., Talpaz, M., Mauro, M., … Apperley, J. F. (2022). Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib. Blood, 140(1, Number 1 Supplement 1), 1495–1497. https://doi.org/10.1182/blood-2022-157822

Chicago

Cortes, Jorge E., Michael W. Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, et al. 2022. “Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib.” Blood 140 (1, Number 1 Supplement 1): 1495–97. doi:10.1182/blood-2022-157822.